tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cancer'

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 12, 2016

All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...

Read More →
0

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

Written by Ι Stock Market Media — July 19, 2016

Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...

Read More →
0

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

Written by Ι Stock Market Media — June 3, 2015

NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.

It was a study ...

Read More →
0

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

On May 28, 2015, Stonegate Capital Partners released an extensive Equity Research Report on PharmaCyte Biotech, Inc.  The firm’s reports are issued to targeted funds, and institutional investors also have access to Stonegate’s research from a variety of services including Bloomberg, Thomson Reuters, Zach’s, Capital IQ, The Markets, Morningstar and FactSet among others. Stonegate has the ability to actively track the institutional investors who access their research.

Click to View Stonegate Capital Partners Equity Research on PharmaCyte ...

Read More →
0

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

Written by Ι Stock Market Media Group  — April 23, 2015

PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce ...

Read More →
0

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

Written by Ι Stock Market Media Group Staff — April 14, 2015

NEW YORK, NY – Plandaí Biotechnology (OTCQB: PLPL) and its operations at the Senteeko tea estate in South Africa are the subject of a newly released video. Stock Market Media Group, a content development investment relations firm, spent a week in South Africa with a camera crew from Bay Colony Media documenting the company’s story, and announced today that the documentary is now available.  

Click Here to View ...

Read More →
0
Page 2 of 11 12345...»
ContactUs.com